If approved, it would mark the first new drug approval to treat the infections in more than a decade, according to Cidara Therapeutics, which developed the drug. The FDA panel’s 14 to 1 vote to recommend rezafungin was based on results from phase 2 and 3 clinical trials, as well as extensive nonclinical findings. The once-weekly treatment demonstrated statistical non-inferiority when compared to caspofungin, the current standard of care given once daily.
The advisory committee’s vote is not binding, though the FDA usually accepts the recommendations in its drug approval decisions.
Cidara has a licensing agreement with Melinta Therapeutics to commercialize the drug in the U.S.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.